Abstract:Objective To investigate the expression and clinical significance of pyruvate dehydrogenase complex E1α subunit (PDHA1) and guanylate binding protein 1 (GBP1) in non-small cell lung cancer (NSCLC). Methods A total of 84 patients with NSCLC were selected from Yantaishan Hospital of Yantai City, Shandong Province from January 2016 to October 2017. The expressions of PDHA1 and GBP1 in the cancerous and adjacent tissues were compared. The patients were divided into PDHA1 positive group (30 cases) and PDHA1 negative group (54 cases) according to the expression of PDHA1 in cancer tissues, and then divided into GBP1 positive group (58 cases) and GBP1 negative group (26 cases) according to the expression of GBP1. The patients were followed up for three years, and the relationship between PDHA1 and GBP1 expression and prognosis was analyzed by survival curve. Results The expression of PDHA1 in the cancerous tissues of NSCLC patients was lower than that in the adjacent tissues, and the expression of GBP1 was higher than that in the adjacent tissues, with statistical significance (P < 0.05). All 84 patients with NSCLC were followed up successfully, and no cases were lost to follow-up. During three years of follow-up, 31 cases died. The 3-year survival rate of PDHA1 positive group was higher than that of PDHA1 negative group, and the 3-year survival rate of GBP1 positive group was lower than that of GBP1 negative group, with statistical significance (P < 0.05). Conclusion Low expression of PDHA1 and high expression of GBP1 in NSCLC tissues are expected to become new molecular markers for prognosis assessment of NSCLC.
李丰环 康丽君. 非小细胞肺癌组织中PDHA1、GBP1的表达及临床意义[J]. 中国医药导报, 2021, 18(26): 107-110.
LI Fenghuan KANG Lijun. Clinical significance and expression of PDHA1 and GBP1 in non-small cell lung cancer. 中国医药导报, 2021, 18(26): 107-110.